Table of Contents
Harold K. Marder, M.D.
First Quarter 2001 Performance
PPT Slide
High Impact Medicines on Three Product Platforms
AHP Pipeline
Drivers of Growth
PREMARIN Family
Effexor® XR
Enbrel®
Significant New Product Approvals
Key Exclusivity Expiration Dates
2001 New Product Opportunities
2001 Life Cycle Management Opportunities
PREVNAR ®
PREVNAR ® Performance
PROTONIX ®
PROTONIX ®
ReFacto®
RAPAMUNE ®
Totelle® 17 ?-estradiol 2mg/Trimegestone 0.5 mg
ALTACE ® (ramipril)
The ALTACE ® Opportunity
CORDARONE ® I.V.
The Next Wave - Pending Regulatory Review
FluMist™
rhBMP-2/ACS
Complementing Internal Productivity with Key External Alliances
The Next Wave: “First in Class” or “Best in Class”
AHP: Building on the Best
|